First-Line Combo for Cisplatin-Ineligible Bladder Cancer Just Misses Positive Result
(MedPage Today) -- SAN FRANCISCO -- Almost half of patients with untreated cisplatin-ineligible advanced urothelial carcinoma responded to the combination of pembrolizumab (Keytruda) and cabozantinib (Cabometyx), but that result fell short of... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 29, 2024 Category: Hematology Source Type: news
Science Sleuths Use Tech to Find Fakery and Plagiarism in Published Research
(MedPage Today) -- Allegations of research fakery at a leading cancer center have turned a spotlight on scientific integrity and the amateur sleuths uncovering image manipulation in published research.
Dana-Farber Cancer Institute in Boston, a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 29, 2024 Category: Hematology Source Type: news
More Evidence That ARSIs for Prostate Cancer Differ in Cognitive Effects
(MedPage Today) -- SAN FRANCISCO -- Two widely used androgen receptor signaling inhibitors (ARSIs) had a similar overall effect on cognitive function in men with metastatic castration-resistant prostate cancer (mCRPC) but differed significantly... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 29, 2024 Category: Hematology Source Type: news
A Win and A Loss for Adjuvant ICIs in Clear Cell Renal Cell Carcinoma
(MedPage Today) -- SAN FRANCISCO -- The use of adjuvant pembrolizumab (Keytruda) boosted overall survival (OS) in post-surgical patients with clear cell renal cell carcinoma (RCC) at risk for recurrence, according to KEYNOTE-564 findings.
Patients... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 29, 2024 Category: Hematology Source Type: news
Another Prostate Cancer Screening Candidate Outperforms Standard PSA Testing
(MedPage Today) -- SAN FRANCISCO -- A multiparametric blood test for prostate cancer showed potential to avoid more than half of unnecessary biopsies without sacrificing accuracy, a large prospective study showed.
In a comparison against the current... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 28, 2024 Category: Hematology Source Type: news
Adjuvant Pembrolizumab Boosts DFS in High-Risk Muscle Invasive Urothelial Cancer
(MedPage Today) -- SAN FRANCISCO -- The use of adjuvant pembrolizumab (Keytruda) more than doubled disease-free survival (DFS) in high-risk muscle-invasive urothelial carcinoma (MIUC) after radical surgery, according to the AMBASSADOR trial... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 28, 2024 Category: Hematology Source Type: news
Cancer After Weight Loss; How Older Adults Use the Healthcare System
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 27, 2024 Category: Hematology Source Type: news
Cabozantinib Plus Atezolizumab Delays Progression in mCRPC
(MedPage Today) -- SAN FRANCISCO -- In patients with metastatic castration-resistant prostate cancer (mCRPC) whose disease progressed on a novel hormonal therapy, the combination of cabozantinib (Cabometyx) plus atezolizumab (Tecentriq) improved... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 27, 2024 Category: Hematology Source Type: news
No Cervical Cancer After HPV Vax; Brain Tumor Blood Test; Weight Loss and Cancer
(MedPage Today) -- A Scottish study found no cases of invasive cervical cancer in women who were vaccinated against human papillomavirus (HPV) when they were 12 or 13 years old. (Journal of the National Cancer Institute)
Meanwhile, women in low... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 26, 2024 Category: Hematology Source Type: news
Olaparib-Abiraterone in Biomarker-Selected mCRPC Tops Each Agent Alone
(MedPage Today) -- SAN FRANCISCO -- Combining a PARP inhibitor with an androgen receptor pathway inhibitor as first-line therapy for biomarker-selected patients with metastatic castration-resistant prostate cancer (mCRPC) significantly improved... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 26, 2024 Category: Hematology Source Type: news
Study Supports High-Dose RT, Long-Term ADT as Standard for High-Risk Prostate Cancer
(MedPage Today) -- SAN FRANCISCO -- Men with high-risk localized prostate cancer lived significantly longer with dose-escalated radiation therapy (RT) plus long-term androgen deprivation therapy (ADT), according to long-term follow-up from a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 26, 2024 Category: Hematology Source Type: news
Two-Stage Screening Strategy for Ovarian Cancer Continues to Show Progress
(MedPage Today) -- A two-stage ovarian cancer screening strategy substantially improved early-stage detection among average-risk postmenopausal women, according to long-term follow-up from a large prospective study.
Combining serial CA125 values... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 25, 2024 Category: Hematology Source Type: news
Apalutamide Makes Its Case in Biochemically Recurrent Nonmetastatic Prostate Cancer
(MedPage Today) -- A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients with high-risk, biochemically... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 24, 2024 Category: Hematology Source Type: news
Neoadjuvant PD-1 Blockade Boosts pCR Rates in Early Esophageal Cancer
(MedPage Today) -- SAN FRANCISCO -- Adding an investigational PD-1 inhibitor to chemotherapy in the neoadjuvant setting significantly improved pathological complete response (pCR) rates for patients with resectable locally advanced esophageal... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 22, 2024 Category: Hematology Source Type: news
Increase in Congenital Syphilis; Decrease in Breast Cancer Mortality
(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of the Texas Tech University Health Sciences Center... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 20, 2024 Category: Hematology Source Type: news
